Frisco, Texas-based Livmor received FDA clearance for the world's first prescribable wearable heart monitor, according to an Oct. 15 press release.
The Livmor Halo System is a continuous heart monitoring system worn on the wrist, and it can enhance detection for intermittent or asymptomatic forms of atrial fibrillation, the release said. The Samsung-run device can be worn daily and is completely noninvasive.
"The FDA 510(k) clearance of our LIVMOR Halo … is a significant milestone for LIVMOR and serves as a foundational cornerstone in our Samsung-based digital health platform," Ken Persen, founder and CEO of Livmor, said in a statement. "This is [a] major step toward achieving our vision of a transformative patient-provider ecosystem that more proactively prevents, detects and manages chronic conditions."
Read the full report here.
More articles on surgery centers:
4 new joint-venture ASCs — September 2020
Work begins on new ASC in Arizona — 3 details
SCA centers added 1,000+ new surgeons in 2020 so far: 5 things to know